On 23 January 2019, Keytone Dairy Corporation Ltd (ASX: KTD) announced that it has launched two new premium powder products - KeyDairyÂ® Diabetic Powder for diagnosed diabetics and KeyDairyÂ® Junior Formula for three to seven-year-old children. The new launches are in line with the companyâs business strategy of expanding its product range and geographical presence.
Founded in 2011, Keytone Dairy is engaged in manufacturing of formulated nutritional dairy products with a market presence in Australia, China and New Zealand. Keytone has three registered proprietary brands namely KeyDairyÂ®, KeyHealthÂ®, and FaceClearÂ®. Its product line includes KeyDairy Whole Milk Powder, KeyDairy Skim Milk Powder, KeyDairy Colostrum Milk Powder, KeyDairy Goat Milk Powder, KeyHealth FaceClear and many more. The company also offers production partnerships, logistic services and packaging solutions to retailers and supermarket chains across key markets.
With key certifications at New Zealand and China, the two nations are major markets for the companyâs product. In New Zealand, Keytone Dairy has been approved by the New Zealand Ministry of Primary Industries and a Halal certification from the Federation of Islamic Associations. Besides, it is also certified by the People's Republic of China.
KeyDairyÂ® Diabetic Powder is a premium dairy powder designed to cater to the diabetic patients specifically. The number of people with type 2 diabetes is increasing across the world as also suggested by the 2017 data of the International Diabetes Federation of over 425 million diabetic patients globally.US$727 billion was spent on diabetes related health care, accounting for 12% of total health care spending in 2017. The Western Pacific region including China, Japan, Indonesia, Australia, and New Zealand, accounts for 33% of all adults living with diabetes globally.
KeyDairyÂ® Diabetic Powder will assist the patient in the management of blood sugar and insulin levels in addition to the prescribed medications. Additionally, the formula provides a good source of essential daily vitamins and minerals. The product is designed for both the domestic and the export markets. With CNCA accreditation, the company will also be exporting the formula to its well-established Chinese market. With Halal certification, the product will also be shipped to the Middle East and the South-East Asian market.
KeyDairyÂ® Junior Formula is a premium dairy product for children aged three to seven years. The formula will assist in immune system development, brain development, resistance to disease, increasing metabolism, red blood cell production, and improving bone density. The formula also provides an essential daily dose of Vitamin A, B, C, and D, in addition to calcium, iron, and protein required for healthy child development. The recommended daily vitamin intake can be difficult to obtain from the available foods and given the prevailing environment in several nations. KeyDairyÂ® Junior Formula has been designed to include a significant portion of the recommended daily doses of these essential vitamins appropriate for this age bracket.
Stock performance: Post the product launches, the shares of Keytone soared by 2.27%, settling at 45 cents on 23 January 2019. Over the past six months, KTD stock has witnessed a strong performance growth of 23.94%. The stock has offered a decent YTD return of 14.29% till date to its investors this year.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
With the pandemic continuing to affect the globe, healthcare companies are evaluating their lead compounds for COVID-19 treatment. Future revenue for these stocks depends on the probability of launching an approved treatment in the market.